A two-part Ph 1 study to investigate GSK3862995B in healthy ...
WEBA two-part Phase 1 randomized, double-blind, placebo-controlled study to investigate safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of GSK3862995B following single ascending doses in healthy participants and repeat doses in participants with Chronic Obstructive Pulmonary Disease.
Site map - Health Research Authority
WEBThe study medicine is a GSK medicine given to treat asthma in adults 18 years of age or older. It is a combination of the following 3 medicines in a single Ellipta inhaler: fluticasone furoate[FF]/umeclidinium bromide[UMEC]/vilanterol trifenatate [VI].
GSK’s new RSV jab set to achieve blockbuster status - Financial Times
WEBJan 29, 2024 · GSK is expected to achieve blockbuster status for its months-old RSV vaccine this week, stealing a march on rival Pfizer and begin allaying long-standing investor concerns about its pipeline.
GlaxoSmithKline focuses on immunology through collaboration
WEBMar 19, 2021 · GSK scientists are using the power of immunology, coupled with genetics and novel technologies, to find the next generation of interventions. The Immunology Network has an external board of advisors who come into GSK twice a …
Manufacturing and Supply - GSK
WEBWe create innovative manufacturing and supply chain solutions that keeps the world’s health at the forefront. It means we make sure that products are manufactured as efficiently as possible and meet the strictest quality standards. Business Operations. Engineering.
GSK to share evidence supporting a personalised approach to …
WEBJul 30, 2020 · GlaxoSmithKline plc (LSE/NYSE: GSK) will share new evidence from the pivotal CAPTAIN study exploring the potential for a biomarker-directed approach to determine appropriate inhaled therapy for patients with uncontrolled asthma.
How GlaxoSmithKline is advancing efficient drug development …
WEBGSK is developing an engineered T-cell receptor, T-cell immunotherapy designed to recognize a tumour-specific antigen and eliminate malignant cells in solid tumours and haematologic...
PathAI and GlaxoSmithKline Sign Multi-Year Agreement to …
WEBBOSTON — April 5, 2022 — PathAI, a global leader in AI-powered pathology, and GlaxoSmithKline (GSK), today announced a strategic multi-year partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAI’s technologies …
Joel PARRY | Team Leader, Investigative Translational Safety
WEBJoel PARRY, Team Leader, Investigative Translational Safety | Cited by 538 | of GlaxoSmithKline, London (GSK) | Read 25 publications | Contact Joel PARRY.
Home | GSK
WEBAt GSK, culture is something we all own. It’s powered by the little things GSK people do every day to help us get ahead of disease together. It drives delivery of our strategy and makes GSK a place people can thrive.
Skip to content